Ulcerative Colitis Clinical Trials in Los Angeles

Showing 41-60 of 331 trials

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

NCT03727880

This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1 antibody, pembrolizumab, with and without study drug, focal adhesion kinase inhibitor (FAK), defactinib, in people with "high risk" resectable (surgically removable) pancreatic cancer. The purpose of this study is to evaluate if reprograming the tumor microenvironment by targeting FAK following chemotherapy can potentiate anti-programmed death-1 (PD-1) antibody.

Resectable Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Ductal Adenocarcinoma

Lei Zheng28 participantsStarted Jun 2019

Los Angeles, California, United States • Baltimore, Maryland, United States • San Antonio, Texas, United States

RECRUITING< 1 mile

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

NCT03004326

Multi-center observational study to evaluate the histopathology and transcriptome of cutaneous lesions in patients with several different types of vasculitis.

Cryoglobulinemic Vasculitis (CV)Drug-induced VasculitisEosinophilic Granulomatosis With Polyangiitis (EGPA)+7 more

Peter Merkel50 participantsStarted Jan 2017

Los Angeles, California, United States • Boston, Massachusetts, United States • Rochester, Minnesota, United States +7 more locations

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

Ulcerative Colitis Trials in Other Cities

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Assessment of CCM in HF With Higher Ejection Fraction

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Effects of Pomegranate Juice on Ulcerative Colitis

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Cardiovascular Structure and Function in the Mucopolysaccharidoses

R-3750 in Patients With Mild to Moderate Ulcerative Colitis

Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

StandUPTV Habits: Feasibility Trial for Maintaining Reductions in Sedentary Screen Time

Other Conditions in Los Angeles